Arrestins in the cardiovascular system

Progress in Molecular Biology and Translational Science

Volumn 118, Issue , 2013, Pages 297-334

  Lymperopoulos, Anastasios ^a   Bathgate, Ashley ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879095096     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394440-5.00012-7     Document Type: Chapter

References (126)

1. M.T. Piascik, and D.M. Perez Alpha1-adrenergic receptors: new insights and directions J Pharmacol Exp Ther 298 2001 403 410
2. B.C. Jensen, T.D. O'Connell, and P.C. Simpson Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure J Mol Cell Cardiol 51 2011 518 528
3. B.C. Jensen, P.M. Swigart, T. De Marco, C. Hoopes, and P.C. Simpson {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium Circ Heart Fail 2 2009 654 663
4. B.W. Van Tassell, M.T. Rondina, F. Huggins, E.M. Gilbert, and M.A. Munger Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction Am Heart J 156 2008 315 321
5. J.M. Stewart, M.B. Patel, and J. Wang Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of LV reserve Am J Physiol 262 2009 H331 H339
6. C. Vecchione, L. Fratta, and D. Rizzoni Cardiovascular influences of alpha1b-adrenergic receptor defect in mice Circulation 105 2002 1700 1707
7. S. Cotecchia The α1-adrenergic receptors: diversity of signaling networks and regulation J Recep Signal Transduct 30 2010 410 419
8. L. Stanasila, L. Abuin, J. Dey, and S. Cotecchia Different internalization properties of the alpha1a- and alpha1b-adrenergic receptor subtypes: the potential role of receptor interaction with beta-arrestins and AP50 Mol Pharmacol 74 2008 562 573
9. M. Phillipp, and L. Hein Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes Pharmacol Ther 101 2004 65 74
10. K.M. Small, K.M. Brown, S.L. Forbes, and S.B. Liggett Polymorphic deletion of three intracellular acidic residues of the alpha2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization J Biol Chem 276 2001 4917 4922
11. K. Nguyen, T. Kassimatis, and A. Lymperopoulos Impaired desensitization of a human polymorphic α2B-adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells Cell Commun Signal 9 2011 5
12. A. Snapir, J. Mikkelsson, M. Perola, A. Penttila, M. Scheinin, and P.J. Karhunen Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death J Am Coll Cardiol 41 2003 190 194
13. F. Von Wowern, K. Bengtsson, U. Lindblad, L. Rastam, and O. Melander Functional variant in the (alpha)2B adrenoceptor gene, a positional candidate on chromosome 2, associates with hypertension Hypertension 43 2004 592 597
14. B. Ohlin, G. Berglund, P.M. Nilsson, and O. Melander Job strain, decision latitude and alpha2B-adrenergic receptor polymorphism significantly interact, and associate with high blood pressures in men J Hypertens 25 2007 1613 1619
15. A. Lymperopoulos, G. Rengo, H. Funakoshi, A.D. Eckhart, and W.J. Koch Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure Nat Med 13 2007 315 323
16. A. Lymperopoulos, G. Rengo, E. Gao, S.N. Ebert, G.W. Dorn 2nd., and W.J. Koch Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction J Biol Chem 285 2010 16378 16386
17. A. Lymperopoulos, G. Rengo, C. Zincarelli, S. Soltys, and W.J. Koch Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity Mol Ther 16 2008 302 307
18. A. Lymperopoulos, G. Rengo, and W.J. Koch Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation Trends Mol Med 13 2007 503 511
19. Q. Wang, J. Zhao, and A.E. Brady Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors Science 304 2004 1940 1944
20. C.L. Schmid, and L.M. Bohn Physiological and pharmacological implications of beta-arrestin regulation Pharmacol Ther 121 2009 285 293
21. G. Rengo, A. Lymperopoulos, and W.J. Koch Future G protein-coupled receptor targets for treatment of heart failure Curr Treat Options Cardiovasc Med 11 2009 328 338
22. G. Rengo, A. Lymperopoulos, and C. Zincarelli Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure Circulation 119 2009 89 98
23. G. Rengo, A. Lymperopoulos, D. Leosco, and W.J. Koch GRK2 as a novel gene therapy target in heart failure J Mol Cell Cardiol 50 2011 785 792
24. A. Lymperopoulos, G. Rengo, and W.J. Koch GRK2 inhibition in heart failure: something old, something new Curr Pharm Des 18 2012 186 191
25. T. Noma, A. Lemaire, and S.V. Naga Prasad Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection J Clin Invest 117 2007 2445 2458
26. D.G. Tilley G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function Circ Res 109 2011 217 230
27. N. Noor, C.B. Patel, and H.A. Rockman β-arrestin: a signaling molecule and potential therapeutic target for heart failure J Mol Cell Cardiol 51 2011 534 541
28. L.M. Luttrell, F.L. Roudabush, and E.W. Choy Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds Proc Natl Acad Sci USA 98 2001 2449 2454
29. D.S. Witherow, T.R. Garrison, W.E. Miller, and R.J. Lefkowitz Beta-arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha Proc Natl Acad Sci USA 101 2004 8603 8607
30. H. Gao, Y. Sun, and Y. Wu Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways Mol Cell 14 2004 303 317
31. P. Zhai, M. Yamamoto, and J. Galeotti Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice J Clin Invest 115 2005 3045 3056
32. M. Aplin, G.L. Christensen, and M. Schneider Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes Basic Clin Pharmacol Toxicol 100 2007 296 301
33. K. Rajagopal, E.J. Whalen, and J.D. Violin Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes Proc Natl Acad Sci USA 103 2006 16284 16289
34. K. Rakesh, B. Yoo, I.M. Kim, N. Salazar, K.S. Kim, and H.A. Rockman Beta-arrestin-biased agonism of the angiotensin receptor induced by mechanical stress Sci Signal 3 2010 ra46
35. J. Kim, L. Zhang, and K. Peppel Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration Circ Res 103 2008 70 79
36. J. Kim, S. Ahn, K. Rajagopal, and R.J. Lefkowitz Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor J Biol Chem 284 2009 11953 11962
37. S. Ahn, J. Kim, M.R. Hara, X.R. Ren, and R.J. Lefkowitz Beta-arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation J Biol Chem 284 2009 8855 8865
38. A. Lymperopoulos, G. Rengo, C. Zincarelli, J. Kim, S. Soltys, and W.J. Koch An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo Proc Natl Acad Sci USA 106 2009 5825 5830
39. A. Lymperopoulos, G. Rengo, C. Zincarelli, J. Kim, and W.J. Koch Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels J Am Coll Cardiol 57 2011 356 365
40. G.E. Morris, C.P. Nelson, N.B. Standen, R.A. Challiss, and J.M. Willets Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2 Cardiovasc Res 85 2010 424 433
41. G.E. Morris, C.P. Nelson, P.J. Brighton, N.B. Standen, R.A. Challiss, and J.M. Willets Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptor-mediated cell signaling and migration in arterial smooth muscle Am J Physiol Cell Physiol 302 2012 C723 C734
42. L.S. Barak, R.H. Oakley, S.A. Laporte, and M.G. Caron Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus Proc Natl Acad Sci USA 98 2001 93 98
43. M.D. Rochdi, G.A. Vargas, and E. Carpentier Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments Mol Pharmacol 77 2010 836 845
44. R.W. Walters, A.K. Shukla, and J.J. Kovacs Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice J Clin Invest 119 2009 1312 1321
45. M. Schaff, N. Receveur, and C. Bourdon β-arrestin-1 participates in thrombosis and regulates integrin aIIbβ3 signalling without affecting P2Y receptors desensitisation and function Thromb Haemost 107 2012 735 748
46. G.E. Morris, C.P. Nelson, and D. Everitt G protein-coupled receptor kinase 2 and arrestin2 regulate arterial smooth muscle P2Y-purinoceptor signalling Cardiovasc Res 89 2011 193 203
47. D. Li, L. D'Angelo, M. Chavez, and D.S. Woulfe Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets J Biol Chem 286 2011 3805 3814
48. J.P. Kukkonen Regulation of receptor-coupling to (multiple) G proteins. A challenge for basic research and drug discovery Receptors Channels 10 2004 167 183
49. O.E. Brodde Beta-adrenoceptors in cardiac disease Pharmacol Ther 60 1993 405 430
50. C. Communal, K. Singh, D.B. Sawyer, and W.S. Colucci Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein Circulation 100 1999 2210 2212
51. A. Chesley, M.S. Lundberg, and T. Asai The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3-kinase Circ Res 87 2000 1172 1179
52. W.Z. Zhu, M. Zheng, W.J. Koch, R.J. Lefkowitz, B.K. Kobilka, and R.P. Xiao Dual modulation of cell survival and cell death by β2-adrenergic signalling in adult mouse cardiomyocytes Proc Natl Acad Sci USA 98 2001 1607 1612
53. G.W. Dorn II, N.M. Tepe, J.N. Lorenz, W.J. Koch, and S.B. Liggett Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq- overexpressing mice Proc Natl Acad Sci USA 96 1999 6400 6405
54. S.B. Liggett, N.M. Tepe, and J.N. Lorenz Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level Circulation 101 2000 1707 1714
55. M.R. Bristow, R. Ginsburg, and V. Umans β1-and β2-adrenergic- receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure Circ Res 59 1986 297 309
56. M.R. Bristow, R. Ginsburg, and W. Minobe Decreased catecholamine sensitivity and β-adrenegic receptor density in failing human hearts N Engl J Med 307 1982 205 211
57. H.A. Rockman, W.J. Koch, and R.J. Lefkowitz Seven-transmembrane-spanning receptors and heart function Nature 415 2002 206 212
58. V.O. Nikolaev, A. Moshkov, and A.R. Lyon Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation Science 327 2010 1653 1657
59. A. Lymperopoulos Beta-arrestin biased agonism/antagonism at cardiovascular seven transmembrane-spanning receptors Curr Pharm Des 18 2012 192 195
60. D.A. Conner, M.A. Mathier, and R.M. Mortensen Beta-arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation Circ Res 81 1997 1021 1026
61. Y. Xiang, and B.K. Kobilka Myocyte adrenoceptor signaling pathways Science 300 2003 1530 1532
62. M.R. Bristow β-Adrenergic receptor blockade in chronic heart failure Circulation 101 2000 558 569
63. M. Packer, M.R. Bristow, and J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355
64. C. Dessy, and J.L. Balligand Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives Adv Pharmacol 59 2010 135 163
65. A. Breit, M. Lagacé, and M. Bouvier Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties J Biol Chem 279 2004 28756 28765
66. R. Gros, J.L. Benovic, C.M. Tan, and R.D. Feldman G-protein-coupled receptor kinase activity is increased in hypertension J Clin Invest 99 1997 2087 2093
67. S.L. Belmonte, and B.C. Blaxall G protein coupled receptor kinases as therapeutic targets in cardiovascular disease Circ Res 109 2011 309 319
68. S. de Foucart, J. Champlain, and R. Nadeau Modulation by beta-adrenoceptors and angiotensin II receptors of splanchnic nerve evoked catecholamine release from the adrenal medulla Can J Physiol Pharmacol 69 1991 1 7
69. S. Foucart, R. Nadeau, and J. de Champlain Local modulation of adrenal catecholamines release by beta-2 adrenoceptors in the anaesthetized dog Naunyn Schmiedebergs Arch Pharmacol 337 1988 29 34
70. S. Billet, F. Aguilar, C. Baudry, and E. Clauser Role of angiotensin II AT1 receptor activation in cardiovascular diseases Kidney Int 74 2008 1379 1384
71. H.A. Rockman, D.J. Choi, N.U. Rahman, S.A. Akhter, R.J. Lefkowitz, and W.J. Koch Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice Proc Natl Acad Sci USA 93 1996 9954 9959
72. A.J. Balmforth, F.H. Shepherd, P. Warburton, and S.G. Ball Evidence of an important and direct role for protein kinase C in agonist-induced phosphorylation leading to desensitization of the angiotensin AT1A receptor Br J Pharmacol 122 1997 1469 1477
73. J.A. Olivares-Reyes, R.D. Smith, L. Hunyady, B.H. Shah, and K.J. Catt Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT1A angiotensin receptor J Biol Chem 276 2001 37761 37768
74. S.J. Mundell, and J.L. Benovic Selective regulation of endogenous G protein-coupled receptors by arrestins in HEK293 cells J Biol Chem 275 2000 12900 12908
75. V.C. Calegari, R.M. Bezerra, and M.A. Torsoni Suppressor of cytokine signaling 3 is induced by angiotensin II in heart and isolated cardiomyocytes, and participates in desensitization Endocrinology 144 2003 4586 4596
76. L. Hein, L. Meinel, R.E. Pratt, V.J. Dzau, and B.K. Kobilka Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand Mol Endocrinol 11 1997 1266 1277
77. W.G. Thomas, T.J. Thekkumkara, and K.M. Baker Cardiac effects of AII. AT1A receptor signaling, desensitization, and internalization Adv Exp Med Biol 396 1996 59 69
78. D.E. Richard, S.A. Laporte, S.G. Bernier, R. Leduc, and G. Guillemette Desensitization of AT1 receptor-mediated cellular responses requires long term receptor down-regulation in bovine adrenal glomerulosa cells Endocrinology 138 1997 3828 3835
79. D.A. Zidar, J.D. Violin, E.J. Whalen, and R.J. Lefkowitz Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands Proc Natl Acad Sci USA 106 2009 9649 9654
80. G. Boerrigter, M.W. Lark, E.J. Whalen, D.G. Soergel, J.D. Violin, and J.C. Burnett Jr. Cardiorenal actions of TRV120027, a novel β-arrestin- biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure Circ Heart Fail 4 2011 770 778
81. M. De Gasparo, K.J. Catt, T. Inagami, J.W. Wright, and T. Unger International union of pharmacology. XXIII. The angiotensin II receptors Pharmacol Rev 52 2000 415 472
82. A. MacKenzie Endothelium-derived vasoactive agents, AT1 receptors and inflammation Pharmacol Ther 131 2011 187 203
83. K.T. Weber Aldosterone in congestive heart failure N Engl J Med 345 2001 1689 1697
84. J.M. Connell, and E. Davies The new biology of aldosterone J Endocrinol 186 2005 1 20
85. A.M. Marney, and N.J. Brown Aldosterone and end-organ damage Clin Sci (Lond) 113 2007 267 278
86. A.M. Richards Mineralocorticoid receptor antagonists for heart failure Expert Opin Pharmacother 12 2011 2801 2815
87. A. Ganguly, and J.S. Davis Role of calcium and other mediators in aldosterone secretion from the adrenal glomerulosa cells Pharmacol Rev 46 1994 417 447
88. Harvey AN, Nguyen K, Lymperopoulos A. GRK2 and beta-arrestins in cardiovascular disease: established and emerging possibilities for therapeutic targeting. Curr Mol Pharmacol 2012. 2011 Jun 15 [Epub ahead of print].
89. G. Turu, L. Szidonya, and Z. Gáborik Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors FEBS Lett 580 2006 41 45
90. M.E. Ivey, N. Osman, and P.J. Little Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis Atherosclerosis 199 2008 237 247
91. N. Vignon-Zellweger, S. Heiden, T. Miyauchi, and N. Emoto Endothelin and endothelin receptors in the renal and cardiovascular systems Life Sci 91 2012 490 500
92. J.D. Stockand Vasopressin regulation of renal sodium excretion Kidney Int 78 2010 849 856
93. R.H. Oakley, S.A. Laporte, J.A. Holt, M.G. Caron, and L.S. Barak Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors J Biol Chem 275 2000 17201 17210
94. A. Lymperopoulos, and A. Bathgate Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown Pharmacogenomics 13 2012 323 341
95. G.B. Lim Vascular disease: no added benefit of niacin with statins Nat Rev Cardiol 9 2011 3
96. J.E. Digby, N. Ruparelia, and R.P. Choudhury Niacin in cardiovascular disease: recent preclinical and clinical developments Arterioscler Thromb Vasc Biol 32 2012 582 588
97. H. Kather, K. Aktories, G. Schulz, and K.H. Jakobs Islet-activating protein discriminates the antilipolytic mechanism of insulin from that of other antilipolytic compounds FEBS Lett 161 1983 149 152
98. N.B. Pike Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid J Clin Invest 115 2005 3400 3403
99. J.G. Richman, M. Kanemitsu-Parks, and I. Gaidarov Nicotinic acid receptor agonists differentially activate downstream effectors J Biol Chem 282 2007 18028 18036
100. G. Semple, P.J. Skinner, and T. Gharbaoui 3-(1H-tetrazol-5-yl)-1,4,5,6- tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice J Med Chem 51 2008 5101 5108
101. C. Gachet P2 receptors, platelet function and pharmacological implications Thromb Haemost 99 2008 466 472
102. A.R. Hardy, P.B. Conley, J. Luo, J.L. Benovic, A.W. Poole, and S.J. Mundell P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms Blood 105 2005 3552 3560
103. A. Baurand, A. Eckly, and B. Hechler Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 67 2005 721 733
104. U.J. Soh, M.R. Dores, B. Chen, and J. Trejo Signal transduction by protease-activated receptors Br J Pharmacol 160 2010 191 203
105. R. Iwamoto, and E. Mekada ErbB and HB-EGF signaling in heart development and function Cell Struct Funct 31 2006 1 14
106. S.M. DeWire, S. Ahn, R.J. Lefkowitz, and S.K. Shenoy Beta-arrestins and cell signaling Annu Rev Physiol 69 2007 483 510
107. G. Esposito, C. Perrino, and A. Cannavo EGFR trans-activation by urotensin II receptor is mediated by beta-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy Basic Res Cardiol 106 2011 577 589
108. P. Zhai, J. Galeotti, and J. Liu An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy Circ Res 99 2006 528 536
109. I.M. Kim, D.G. Tilley, and J. Chen Beta-blockers alprenolol and carvedilol stimulate betaarrestin-mediated EGFR transactivation Proc Natl Acad Sci USA 105 2008 14555 14560
110. D.G. Tilley, I.M. Kim, P.A. Patel, J.D. Violin, and H.A. Rockman Beta-arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling J Biol Chem 284 2009 20375 20386
111. N.J. Smith, H.W. Chan, and H. Qian Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy Hypertension 57 2011 973 980
112. L. Barki-Harrington, L.M. Luttrell, and H.A. Rockman Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo Circulation 108 2003 1611 1618
113. D. Cervantes, C. Crosby, and Y. Xiang Arrestin orchestrates crosstalk between G protein-coupled receptors to modulate the spatiotemporal activation of ERK MAPK Circ Res 106 2010 79 88
114. 2-adrenergic receptor J Biol Chem 283 2008 5669 5676
115. A.Y. Woo, T.B. Wang, and X. Zeng Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes Mol Pharmacol 75 2009 158 165
116. M. Azzi, P.G. Charest, and S. Angers β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors Proc Natl Acad Sci USA 100 2003 11406 11411
117. J.W. Wisler, S.M. DeWire, and E.J. Whalen A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling Proc Natl Acad Sci USA 104 2007 16657 16662
118. M. Fiuzat, and C.M. O'Connor Bucindolol: new hopes from reviewing past data Drugs Today (Barc) 47 2011 347 351
119. 2-adrenergic receptor characterized by 19F-NMR Science 335 2012 1106 1110
120. D.M. Rosenbaum, S.G. Rasmussen, and B.K. Kobilka The structure and function of G-protein-coupled receptors Nature 459 2009 356 363
121. H. Peng, R.A. Bond, and B.J. Knoll The effects of acute and chronic nadolol treatment on β2AR signaling in HEK293 cells Naunyn Schmiedebergs Arch Pharmacol 383 2011 209 216
122. A. Lymperopoulos, G. Rengo, V. Magafa, P. Cordopatis, and W.J. Koch Biased agonism/antagonism of β-arrestin activation by the angiotensin II type 1 receptor: a study of sartans and angiotensin II analogs using aldosterone turnover as a readout J Card Fail Suppl 16 2010 S30 S31
123. A.C. Holloway, H. Qian, and L. Pipolo Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors Mol Pharmacol 61 2002 768 777
124. H. Wei, S. Ahn, and S.K. Shenoy Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 Proc Natl Acad Sci USA 100 2003 10782 10787
125. A.K. Shukla, J.D. Violin, E.J. Whalen, D. Gesty-Palmer, S.K. Shenoy, and R.J. Lefkowitz Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors Proc Natl Acad Sci USA 105 2008 9988 9993
126. B. Zimmerman, A. Beautrait, and B. Aguila Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs Sci Signal 5 2012 ra33